Press Releases 2021

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Investigational Drug Candidate AMV564 Demonstrates Safety with Evidence of Anti-tumor T cell Expansion and One Complete Response, Multiple Mixed Responses and Durable Disease Stabilization in Solid Tumor Patients No Cytokine Release Syndrome (CRS) reported in patients treated...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Cytokine data from cancer patients reveal a unique profile for AMV564 therapy, with strong induction of IFN╬│ and other cytokines and chemokines that drive T cell activation and trafficking, and limited levels of IL6. As MDSC produce...